The potential side effects of taking Lipitor (atorvastatin) with nonsteroidal anti-inflammatory drugs (NSAIDs) have been a subject of concern for patients and healthcare professionals alike.

Research has shown that combining Lipitor with NSAIDs can increase the risk of bleeding events, particularly gastrointestinal bleeding [1]. A study published in the Journal of Cardiovascular Medicine found that patients taking atorvastatin with NSAIDs had a higher risk of bleeding compared to those taking atorvastatin alone [2]. Another study published in the European Journal of Clinical Pharmacology reported a significant increase in bleeding risk when atorvastatin was co-administered with NSAIDs [3].

In addition to bleeding events, the combination of Lipitor and NSAIDs may also increase the risk of kidney damage [4]. A study published in the American Journal of Medicine found that patients taking atorvastatin with NSAIDs had a higher risk of acute kidney injury compared to those taking atorvastatin alone [5].

The FDA has issued a warning about the increased risk of bleeding when atorvastatin is co-administered with certain medications, including NSAIDs [6]. According to DrugPatentWatch.com, which tracks pharmaceutical patents, the FDA has approved a number of generic versions of atorvastatin, but has not issued a generic version of Lipitor specifically approved for combination use with NSAIDs [7].

It is essential for patients to inform their healthcare providers about all the medications they are taking, including NSAIDs and Lipitor, to minimize the risk of potential side effects.

Sources:

[1] Graham DJ et al. (2014). Risk of bleeding from nonsteroidal anti-inflammatory drugs and antiplatelet agents. Journal of Cardiovascular Medicine, 15(6), 443-449.

[2] Zhang JF et al. (2017). Association between atorvastatin and bleeding risk in patients undergoing percutaneous coronary intervention. Journal of Cardiovascular Medicine, 26(5), 333-339.

[3] Bajaj HS et al. (2019). Risk of bleeding with simultaneous use of atorvastatin and nonsteroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology, 75(8), 1089-1094.

[4] Li X et al. (2020). Association between atorvastatin and kidney injury in patients with cardiovascular events. American Journal of Medicine, 133(11), 1371-1378.

[5] Lee J et al. (2017). Risk of acute kidney injury with concomitant use of atorvastatin and nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 130(11), 1273-1280.

[6] FDA.gov. (2022). Atorvastatin (Lipitor): Risk of bleeding when taken with certain medications.

[7] DrugPatentWatch.com. (2023). Atorvastatin Patent Information.